An overview of ECD and its status is given by Dr. Gaurav Goyal with the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham. A summary of the research and clinical aspects of the disease are also shared.
Early in his career, Dr. Goyal developed a special interest in histiocytic disorders, owing to the unique challenges and the unmet need posed by them. His passion to help these underserved patients is evident.
During his career, Dr. Goyal established the Histocytosis Working Group (HWG), a multidisciplinary group focused on advancing the understanding of these disorders, and a tissue/blood biorepository linked to clinical data. Dr. Goyal initiated several projects aimed at understanding the epidemiology, clinical features, and outcomes of various histiocytic disorders, which yielded multiple peer-reviewed publications. He led the first guideline document to help diagnose histiocytic disorders through the HWG and the updated international Erdheim-Chester disease (ECD) guidelines. In his newest work, Histiocytic Disorder Survivor Study, he aims to describe the overall and cause-specific mortality associated with ECD. The study aims to understand the effects of ECD and its treatments on patient health and survival.
Негізгі бет Erdheim-Chester disease: What do we know a century later?
Пікірлер